Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29155624.
- Also identified by DOI 10.1148/radiol.2017161517 and PMC identifier 5708287.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with prostate cancer who have regional lymph node (LN) metastases face an increased risk of death from disease and are therefore treated aggressively. Surgical LN dissection is the established method of staging regional nodes; however, this invasive technique carries substantial morbidities and a noninvasive imaging method is needed to reduce or eliminate the need for extended pelvic LN dissections (ePLND). Conventional computed tomography and magnetic resonance (MR) imaging have proven insensitive and nonspecific because both use nodal size criteria, which is notoriously inaccurate. Novel imaging techniques such as functional MR imaging by using diffusion-weighted MR imaging, MR lymphography with iron oxide particles, and targeted positron emission tomography imaging are currently under development and appear to improve LN staging of prostate cancer. Although progress is being made in staging nodes with imaging, it has not reached the point of replacing ePLND. In this review, the strengths and limitations of these new functional and targeted LN imaging techniques for prostate cancer are discussed. <sup>©</sup> RSNA, 2017.
Medical subject headings
- Lymph Nodes
- Lymphatic Metastasis
- Magnetic Resonance Imaging
- Molecular Diagnostic Techniques
- Positron-Emission Tomography
- Prostatic Neoplasms